Should we consider MMF therapy after rituximab for nephrotic syndrome?
- PMID: 21533869
- DOI: 10.1007/s00467-011-1894-x
Should we consider MMF therapy after rituximab for nephrotic syndrome?
Abstract
The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum half-life following the recovery of CD20-positive cells. The addition of mycophenolate mofetil (MMF) as a maintenance therapy is also an attractive option, but one which requires testing in a prospective randomized clinical trial with therapeutic drug monitoring and mechanistic ancillary studies.
Comment on
-
Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.Pediatr Nephrol. 2011 Oct;26(10):1823-8. doi: 10.1007/s00467-011-1886-x. Epub 2011 May 10. Pediatr Nephrol. 2011. PMID: 21556716
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
